V3-substanceAdminSubstitution.xml

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

<ValueSet xmlns="http://hl7.org/fhir">
  <id value="v3-substanceAdminSubstitution"/>
  <meta>
    <lastUpdated value="2016-03-23T00:00:00.000+11:00"/>
    <profile value="http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p>Release Date: 2016-03-23</p>

      <table class="grid">
 
        <tr>
          <td>
            <b>Level</b>
          </td>
          <td>
            <b>Code</b>
          </td>
          <td>
            <b>Display</b>
          </td>
          <td>
            <b>Definition</b>
          </td>
        </tr>
 
        <tr>
          <td>1</td>
          <td>
            <span style="color: grey">
              <i>(_ActSubstanceAdminSubstitutionCode)</i>
            </span> 
            <b>
              <i>Abstract</i>
            </b>
          </td>
          <td>
            <a name="_ActSubstanceAdminSubstitutionCode"> </a>
          </td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product that may potentially have different ingredients, but having the same biological
               and therapeutic effects.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  E
            <a name="E"> </a>
          </td>
          <td>equivalent</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               bioequivalent and therapeutically equivalent product.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    EC
            <a name="EC"> </a>
          </td>
          <td>equivalent composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted with another product that
               is a:
            <br/>

                        
                           pharmaceutical alternative containing the same active ingredient
               but is formulated with different salt, ester
                           pharmaceutical equivalent that has the same active ingredient,
               strength, dosage form and route of administration
                        
                        
                           Examples: 
                        
            <br/>

                        
                           
                              Pharmaceutical alternative: Erythromycin Ethylsuccinate
               for Erythromycin Stearate
                           
                              Pharmaceutical equivalent: Lisonpril for Zestril
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      BC
            <a name="BC"> </a>
          </td>
          <td>brand composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted between equivalent Brands
               but not Generics
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Zestril  for Prinivil
                           Coumadin for Jantoven
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      G
            <a name="G"> </a>
          </td>
          <td>generic composition</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               equivalent Generics but not Brands
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    TE
            <a name="TE"> </a>
          </td>
          <td>therapeutic alternative</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product having the same therapeutic objective and safety profile.
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           ranitidine for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TB
            <a name="TB"> </a>
          </td>
          <td>therapeutic brand</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Brands but not Generics
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Zantac for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TG
            <a name="TG"> </a>
          </td>
          <td>therapeutic generic</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Generics but not Brands
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Ranitidine  for cimetidine
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  F
            <a name="F"> </a>
          </td>
          <td>formulary</td>
          <td>
                        
                           Description: This substitution was performed or is permitted
               based on formulary guidelines. 
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  N
            <a name="N"> </a>
          </td>
          <td>none</td>
          <td>
                        No substitution occurred or is permitted.
            <br/>

                     
          </td>
        </tr>

      </table>

    </div>
  </text>
  <url value="http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution"/>
  <version value="2016-03-23"/>
  <name value="v3 Code System substanceAdminSubstitution"/>
  <status value="active"/>
  <experimental value="false"/>
  <publisher value="HL7, Inc"/>
  <contact>
    <telecom>
      <system value="other"/>
      <value value="http://hl7.org"/>
    </telecom>
  </contact>
  <date value="2016-03-23"/>
  <description value=" Identifies what sort of change is permitted or has occurred between the therapy that
     was ordered and the therapy that was/will be provided."/>
  <compose>
    <include>
      <system value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/>
    </include>
  </compose>
</ValueSet>